PRESENTATION · Jul 2025 · PDF

ADH1 - ENDO 2025 - Baseline Characteristics of Pediatric Participants in the CLARIFY Disease Monitoring Study

PRESENTATION · Jul 2025 · PDF

Encaleret - ADH1 - ENDO 2025 - Phase 2 Over 42 Months Data Results

PRESENTATION · Jul 2025 · PDF

Encaleret - ADH1 - ENDO 2025 - CALIBRATE-PEDS Phase 2/3 Study Design

PRESENTATION · Jul 2025 · PDF

ADH1- ENDO 2025 - Findings from Sponsored Genetic Testing Program Show Gain-of-function CASR Variants Identified as a Major Genetic Contributor of Non-Surgical Hypoparathyroidism

PUBLICATION · May 2025 · PDF

Journal of the American College of Cardiology, Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - Improvement in Serum TTR Levels in Wild-type or Variant Transthyretin Amyloid Cardiomyopathy

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - PNS 2025 - Low Transthyretin Is Associated With Severe Comorbidities

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis AG10 TTR - ESC-HF 2025 - Disease Progression Among Patients for ATTR-CM in a Real-world Setting

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - Atrial Fibrillation-related Events in Patients with ATTR-CM in ATTRibute-CM

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - Functional Capacity and Quality of Life in Variant ATTR-CM from ATTRibute-CM